本页面由Tiger Trade Technology Pte. Ltd.提供服务

Neumora Therapeutics, Inc.

1.53
-0.1050-6.44%
盘前1.580.0550+3.61%08:50 EDT
成交量:115.54万
成交额:183.84万
市值:2.87亿
市盈率:-1.25
高:1.65
开:1.58
低:1.51
收:1.63
52周最高:3.65
52周最低:0.8302
股本:1.88亿
流通股本:1.16亿
量比:1.19
换手率:1.00%
股息:- -
股息率:- -
每股收益(TTM):-1.2237
每股收益(LYR):-1.4501
净资产收益率:-187.11%
总资产收益率:-73.85%
市净率:6.44
市盈率(LYR):-1.05

数据加载中...

公司资料

公司名字:
Neumora Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2019
员工人数:
63
公司地址:
260 Arsenal Place,Suite 1,Watertown,Massachusetts,United States
邮编:
02472
电话:
传真:
- -
简介:
Neumora Therapeutics, Inc.最初于2019年11月在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,旨在通过提出下一代脑渗透化学新疗法,为患者提供更好的治疗结果和生活质量,以应对其这一代人面临的最大医疗挑战。该公司的治疗管道目前包括针对各种服务不足的流行疾病的新作用机制的项目。

董事

名称
职位
Henry O. Gosebruch
President, Chief Executive Officer and Director
Paul L. Berns
Executive Chairman
Alaa Halawa
Director
David Piacquad
Director
Kristina Burow
Director
Matthew Fust
Director
Maykin Ho
Director

股东

名称
职位
Henry O. Gosebruch
President, Chief Executive Officer and Director
Carol Suh
Chief Operating Officer
Joshua Pinto
Chief Financial Officer
Daljit Singh Aurora
Chief Strategy Officer
Lori Houle
Chief Quality Officer
Maryjo Chamberlain Tharp
Chief Business Officer
Michael Gold
Chief Medical Officer
Nicholas Brandon
Chief Scientific Officer
Paul L. Berns
Executive Chairman
Raj Manchanda
Chief Technical Operations Officer
Robert Lenz
Head of Research and Development